Importance of biomarkers in glioblastomas patients receiving local BCNU wafer chemotherapy.
Steffi UrbschatChristoph SipplJana EngelhardtKai KammersJoachim OertelRalf KetterPublished in: Molecular cytogenetics (2017)
A clinical benefit for the widespread use of additional carmustine wafer implantation could not be found. However, carmustine wafer implantation shows a significantly improved overall survival if parts of chromosome 10 or chromosome 13 are deleted. In cases of 4q12 amplification and in cases of a methylated p15 promotor, the use of carmustine wafers is especially not recommended. The MGMT promoter methylation is a strong prognostic Biomarker for benefit from temozolomide and BCNU chemotherapy.